As regulatory, pricing and policy dynamics whipsaw in the United States, healthcare and life sciences firms are facing enormous pressures to keep profits rising, with those challenges now “becoming more acute by the quarter,” according to an inaugural industry distress survey from consulting firm AlixPartners.